<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00263003</url>
  </required_header>
  <id_info>
    <org_study_id>PM_L_0094</org_study_id>
    <nct_id>NCT00263003</nct_id>
  </id_info>
  <brief_title>Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension</brief_title>
  <official_title>A Randomized, Open Label Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Study Objectives :&#xD;
&#xD;
        -  To demonstrate the reduction in office Blood Pressure following a 8-week regimen of&#xD;
           irbesartan / hydrochlorothiazide using irbesartan as a reference.&#xD;
&#xD;
        -  To demonstrate the reduction in office Blood Pressure after 4-week regimen of irbesartan&#xD;
           / hydrochlorothiazide using irbesartan as a reference.&#xD;
&#xD;
        -  To compare the response rate (defined as office Systolic Blood Pressure/Diastolic Blood&#xD;
           Pressure reduce more than 10mmHg from Week 0) of patients after 4-week and 8-week&#xD;
           regimen of irbesartan / hydrochlorothiazide versus irbesartan.&#xD;
&#xD;
        -  To compare the proportion of patients requiring titration after 4-week regimen of&#xD;
           irbesartan/hydrochlorothiazide versus irbesartan&#xD;
&#xD;
        -  To ascertain the safety and tolerability of irbesartan / hydrochlorothiazide versus&#xD;
           irbesartan when administered once daily&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the reduction in office BP following a 8-week regimen of irbesartan / hydrochlorothiazide versus irbesartan</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the reduction in office BP following a 4-week regimen of irbesartan / hydrochlorothiazide versus irbesartan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the response rate (defined as office SBP/DBP reduce more than 10mmHg from week 0) of patients after 4-week and 8-week regimen of irbesartan/hydrochlorothiazide versus irbesartan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the proportion of patients requiring titration after 4-week regimen of irbesartan/hydrochlorothiazide versus irbesartan</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ascertain the safety and tolerability of irbesartan/hydrochlorothiazide versus irbesartan when administered once daily.</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan/hydrochlorothiazide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with mild to moderate hypertension with office Diastolic Blood Pressure (DBP)&#xD;
             90-109 mmHg and/or Systolic Blood Pressure (SBP) 140-179 mmHg&#xD;
&#xD;
          -  All women of child-bearing potential must have negative urine pregnancy tests within a&#xD;
             week prior to initiation of therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  females who are pregnant or breast feeding&#xD;
&#xD;
          -  office DBP ≥ 110 mmHg or office SBP ≥ 180 mmHg&#xD;
&#xD;
          -  history of significant cardiovascular diseases which includes:&#xD;
&#xD;
               -  acute myocardial infarction within six months or any ischemic heart disease&#xD;
                  requiring medication.&#xD;
&#xD;
               -  cerebrovascular disease&#xD;
&#xD;
          -  history of significant renal diseases including:&#xD;
&#xD;
               -  serum creatinine &gt; 3.0 mg/dl.&#xD;
&#xD;
               -  creatinine clearance &lt; 30 ml/min.&#xD;
&#xD;
          -  severe biliary cirrhosis and cholestasis&#xD;
&#xD;
          -  refractory hypokalemia, hypercalcemia&#xD;
&#xD;
          -  history of autoimmune disease, collagen vascular disease, multiple drug allergies,&#xD;
             bronchospastic disease or other malignancies requiring current medication&#xD;
&#xD;
          -  hepatic disease as indicated by any of the following:&#xD;
&#xD;
               -  SGOT or SGPT &gt;3 x upper limit of normal.&#xD;
&#xD;
               -  Serum bilirubin &gt; 2 x upper limit of normal.&#xD;
&#xD;
          -  any other condition or therapy that, in the investigator's opinion, or as indicated in&#xD;
             the product(s) label may pose a risk to the patient or interfere with the study&#xD;
             objectives.&#xD;
&#xD;
          -  any other investigational drug given within 30 days of initiation of therapy, and&#xD;
             participation in other clinical studies while enrolled in this protocol.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon CHANG, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>December 6, 2007</last_update_submitted>
  <last_update_submitted_qc>December 6, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2007</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

